INCB 50465-313: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants with Myelofibrosis

Principal investigator: Minna Lehto
HUS Helsinki University Hospital, Comprehensive Cancer Center

Link to the ClinicalTrials.gov study website